肉毒毒素 一种用于中风后上肢的注射和亚洲国家中心的康复实践
Raymond L Rosales1,2, Nicholas V C Chia3, Witsanu Kumthornthip4
1Department of Neurology and Psychiatry, University of Santo Tomas, Manila, Philippines.
毒素A (BoNT-A) 在亚洲患者中有效管理中风后上肢性,显著改善了目标的实现. 大多数患者经历了功能改善,证明了BoNT-A.
科学领域:
- 神经学 神经学
- 康复医学 康复医学 康复医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 脑卒中后的上肢是常见的,使人虚弱的疾病.
- 毒素A (BoNT-A) 是一种被公认的治疗焦点的方法.
- 在亚洲人群中对BoNT-A有效性的现实数据有限.
研究的目的:
- 描述在亚洲患者中使用BoNT-A治疗中风后上肢的现实实践和结果.
- 在这个患者群体中,评估目标实现作为主要结果.
主要方法:
- 一项前性观察性研究 (NCT01020500) 的子组分析,该研究涉及患有中风后上肢的成年患者.
- 患者接受了常规的性管理,包括BoNT-A治疗.
- 使用目标实现量化 (GAS) 来衡量目标实现.
主要成果:
- 招募了51名亚洲患者,其并发性认知/情绪问题率较低.
- 大多数患者 (94.1%) 接受了abobotulinumtoxinA,中位数剂量为500单位.
- 74.5%的人实现了其主要的功能目标,平均GAS T得分的改善为20.9 (p < 0.001);96.1%的人显示整体改善.
结论:
- 在亚洲环境下,BoNT-A治疗对亚洲中风后上肢动的目标实现产生了临床显著的影响.
- 这些发现支持使用BoNT-A作为在现实世界亚洲临床实践中的有效管理策略.
更多相关视频
04:49Author Spotlight: Enhancing Post-Stroke Upper Limb Rehabilitation with Robotic Technologies for Improved Motor Recovery and Functional Outcomes
Published on: September 6, 2024
05:28Author Spotlight: Enhancing Upper Limb Rehabilitation in Stroke Patients Through Advanced Robotic and Neuromodulation Technologies
Published on: October 11, 2024
相关概念视频
Skeletal Muscle Relaxants: Therapeutic Uses
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Depolarizing Blockers: Pharmocokinetics
Classification of Skeletal Muscle Relaxants
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Depolarizing Blockers: Mechanism of Action
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
